German drugmaker Boehringer Ingelheim has presented new analyses on the use of Ofev (nintedanib) in treating idiopathic pulmonary fibrosis (IPF), supporting existing safety and efficacy data.
Ofev is one of the first drug treatments approved for IPF by the US Food and Drug Administration, and the only kinase inhibitor approved to treat this disease.
The results, which were presented at the 2017 American Thoracic Society conference, build on earlier positive trial data, announced in early 2016 and in the latter part of that year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze